The Dutch vaccine developer DCprime BV has entered a research collaboration with the University Medical Center of Groningen to design a therapeutic vaccine for ovarian cancer using an approach that targets residual disease after a standard-of-care treatment.
The goal of the partnership is to design a novel relapse vaccine for ovarian cancer and to prepare for a clinical trial in ovarian cancer patients. DCprime will work with the university’s department of obstetrics and gynecology which is led by Hans Nijman.